American Pharmacy News Reports Stories

Pharmacy Times’ departments work together to deliver content on the evolving pharmacy industry.

Pharmacy Times, the leading media resource for pharmacists and the pharmacy industry, ranked highest in ad visibility and highest in readership in the 2017 Kantar Media Pharmacy Readership study. Read More »

Neovac moves forward with dermatomyositis treatment

The trial will examine the immunogenicity, tolerability and biological and clinical efficacy of IFNalpha Kinoid.

Neovacs, a company focusing on immunotherapies that treat autoimmune diseases, recently announced its Investigation New Drug application for IFNalpha Kinoid was cleared by the U.S. Food and Drug Administration. Read More »

Collaborative drug for AML gains FDA approval

$IDHIFA is a treatment for adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.$

Celgene Corp. and Agios Pharmaceuticals Inc. recently received U.S. Food and Drug Administration approval for IDHIFA as a treatment for adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Read More »

Spectrum Pharmaceuticals completes enrollment for Rolontis study

CEO Rajesh Shrotriya said the drug can change the company’s growth timeline.

Spectrum Pharmaceuticals Inc., a biotechnology company focusing on hematology and oncology, recently completed enrollment for its Rolontis Phase 3 Advance pivotal study. Read More »

Vertex nets FDA approval for Kalydeco to treat cystic fibrosis

Kalydeco is administered orally in 150 mg tablet doses for patients age 6 years and older.

Following successful clinical results, Vertex Pharmaceuticals Inc. recently gained approval from the U.S. Food and Drug Administration (FDA) to treat more than 600 cystic fibrosis (CF) patients with its proprietary Kalydeco (ivacaftor) product. Read More »

Dexrazoxane from Cumberland Pharmaceuticals approved for U.S. oncology patients

Totect is approved by the U.S. Food and Drug Administration as an oncology intervention.

Cumberland Pharmaceuticals, specializing in therapies for underserved populations, has begun shipping its Totect brand of dexrazoxane, for alleviating certain side effects of chemotherapy during cancer treatment, to U.S. wholesalers. Read More »

Zoetis acquires Nexvet Biopharma for pet pain management products

Zoetis’ product line features chronic pain management meds for dogs and cats.

Animal health specialist firm Zoetis of Parsippany, New Jersey recently completed an approximately $85 million acquisition of Irish biologic therapeutics business Nexvet Biopharma PLC, with the deal expected to boost the company’s market share. Read More »

Bracco obtains FDA approval for Varibar Nectar Oral Suspension

Viscosity, important in modified barium swallow exams, was designed to provide tolerable texture and taste.

To better assess patients’ oral and pharyngeal functioning for the purpose of easing swallowing disorders, the U.S. Food and Drug Administration recently approved Bracco Diagnostics Inc.’s Varibar Nectar (barium sulfate) Oral Suspension. Read More »

Spectrum Pharmacy Products and IPA form partnership

Spectrum will offer IPA members some of the broadest selection of compounding chemicals in the industry.

Spectrum Pharmacy Products, a top manufacturer and distributor of pharmaceutical chemicals and supplies, is partnering with the Independent Pharmacy Alliance (IPA), a retail pharmacy and trade group that represents thousands of pharmacies in the Northeastern U.S., PR Newswire reported. Read More »

Parexel leaders named to 2017 PharmaVOICE's 100 inspiring people

Dr. Sy Pretorius has worked at Parexel for over two decades in global managerial roles.

Boston-based biopharmaceutical firm Parexel International Corp. has had two of its leaders earn a place on PharmaVOICE magazine’s annual list of the life science industry’s top 100 “inspiring people” for their overall industry contribution and highest level of commitment. Read More »

Immunalysis’ Sefria earns FDA approval for opioid screening

Until now, immunoassay tests for fentanyl were restricted to forensic use.

Formulated to detect the presence of the potent opioid fentany in urine, California-based Immunalysis Corp.’s branded immunoassay Sefria — the first of its kind — recently achieved 510(k) clearance from the U.S. Food and Drug Administration. Read More »

Silvergate delivers FDA-approved oral med Xatmep for children

For leukemia patients, the medication is meant to be taken in combination with chemotherapy.

Filling a need for those youngsters who fear needles or find pills unmanageable, Denver-based Silvergate Pharmaceuticals Inc. recently released Xatmep, the first methotrexate oral solution to gain approval from the U.S. Food and Drug Administration. Read More »

Innovus Pharma seeks to release hemorrhoid pain relief cream in Canada

Innovus Pharmaceuticals Inc., an expanding commercial-stage medication company that provides over-the-counter products for both men and women, will be filing a product licence application in Canada for its drug, Xyralid. Read More »

LabCorp to acquire Chiltern in $1.2 billion cash deal

Chiltern expects 2017 revenue of approximately $550 million.

LabCorp, a provider of diagnostic solutions and breakthrough medicines, recently announced plans for its all-cash acquisition of international contract research firm Chiltern of England for approximately $1.2 billion, enhancing LabCorp’s portfolio and capabilities. Read More »

Insys Therapeutics rolls out ‘milestone’ Syndros formula

Dronabinol is a pharmaceutical cannabinoid.

Phoenix-based Insys Therapeutics Inc. recently revealed that its new branded liquid formulation Syndros (dronabinol oral solution) is on the market to address side effects of AIDS and chemotherapy such as weight loss and related symptoms. Read More »

FDA plans to curb tobacco deaths with new regulation

Ninety percent of adult smokers began the habit before the age of 18.

The U.S. Food and Drug Administration is creating new regulation on tobacco and nicotine to reduce diseases and death brought on by tobacco use. Read More »

Eagle Pharmaceuticals receives FDA reply for Ryanodex

The FDA has asked Eagle to perform another clinical trial for Ryanodex as it pertains to treating EHS in tandem with external cooling treatments.

In answer to New Jersey-based Eagle Pharmaceuticals Inc.’s New Drug Application (NDA) for Ryanodex (dantrolene sodium) to treat exertional heat stroke (EHS), the U.S. Food and Drug Administration (FDA) recently issued a Complete Response Letter. Read More »

Biologics named limited distributor of Nerlynx

Biologics uses a “high-touch care model” emphasizing a team approach to the patient’s experience.

Los Angeles-based Puma Biotechnology Inc.’s FDA-approved Nerlynx (neratinib) tablets — a kinase inhibitor developed to treat breast cancer — will be circulated by Cary, North Carolina’s Biologics Inc. as per a limited distribution agreement between the companies. Read More »

Teligent's topical erythromycin gel receives FDA approval